Lincoln Pharma announces 31st AGM voting results; all resolutions passed including ₹1.80 dividend and director re-appointments
Lincoln Pharmaceuticals announced that all resolutions, including a ₹1.80 dividend and director re-appointments, were passed at its 31st AGM on September 30, 2025.
The announcement confirms the successful passing of all resolutions at the AGM, including a dividend declaration and re-appointment of key management, which provides stability and follows expected corporate governance. This is a routine but positive outcome for stakeholders.
All resolutions, including the declaration of a dividend and re-appointment of key management personnel, were passed by shareholders with an overwhelming majority, indicating strong approval and stable corporate governance.
Lincoln Pharmaceuticals Limited has submitted the voting results and Scrutinizer's Report for its 31st Annual General Meeting (AGM) held on Tuesday, September 30, 2025, via Video Conferencing/Other Audio-Visual Means. All resolutions proposed at the AGM were passed with the requisite majority of shareholders. * Shareholders adopted the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2025. * A dividend of ₹1.80/- (18%) per equity share for the financial year 2024-2025 was declared. * Mr. Ashish Rajanikant Patel and Mr. Rajanikant Gulabdas Patel were re-appointed as Directors. * Mr. Mahendra G. Patel was re-appointed as Managing Director for a period of 5 years with effect from October 01, 2025. * Mr. Hashmukh I. Patel was re-appointed as a Whole Time Director for a period of 5 years with effect from October 01, 2025. * Mr. Ashish R. Patel was re-appointed as a Whole Time Director for a period of 5 years with effect from November 14, 2025. * Mr. Munjal M. Patel was re-appointed as a Whole Time Director for a period of 5 years with effect from November 14, 2025. * The remuneration payable to Kiran J. Mehta & Co., Cost Accountants, for the Financial Year ending March 31, 2026, was ratified. * M/s. Ankit Sethi & Associates were appointed as Secretarial Auditors for a first term of 5 consecutive years.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.